FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169082093> ?p ?o ?g. }

• W2169082093 endingPage "756" @default.
• W2169082093 startingPage "748" @default.
• W2169082093 abstract "Background & Aims Boceprevir with peginterferon/ribavirin (BOC/PR) leads to significantly higher sustained virological response (SVR) rates in patients with chronic hepatitis C and partial response or relapse after prior treatment with peginterferon/ribavirin. We studied the efficacy of BOC/PR in patients with prior treatment failure, including those with a null response (<2-log10 decline in HCV RNA), to peginterferon/ribavirin. Methods Patients in the control arms of boceprevir Phase 2/3 studies who did not achieve SVR were re-treated with BOC/PR for up to 44 weeks. Patients enrolling >2 weeks after end-of-treatment in the prior study received PR for 4 weeks before adding boceprevir. Results Of 168 patients enrolled, four discontinued from the PR lead-in and 164 received BOC/PR. Baseline viral load was >800,000 IU/ml in 77% of patients; 62% had HCV genotype 1a, and 10% were cirrhotic. In the ITT analysis (all 168 patients), SVR was achieved in 20 (38%) of 52 patients with prior null response, 57 (67%) of 85 with prior partial response, and 27 (93%) of 29 with prior relapse. In the mITT analysis (164 BOC/PR-treated patients), SVR rates were 41% (20/49), 67% (57/85), and 96% (27/28), respectively. SVR was achieved by 48% of patients with <1-log10 decline in HCV-RNA after lead-in and 76% of those with ⩾1-log10 decline or undetectable HCV-RNA after lead-in. The most common adverse events were anemia (49%), fatigue (48%), and dysgeusia (35%); 8% of patients discontinued due to adverse events. Conclusions Re-treatment with BOC/PR improved SVR rates in all patient subgroups, including those with prior null response. Boceprevir with peginterferon/ribavirin (BOC/PR) leads to significantly higher sustained virological response (SVR) rates in patients with chronic hepatitis C and partial response or relapse after prior treatment with peginterferon/ribavirin. We studied the efficacy of BOC/PR in patients with prior treatment failure, including those with a null response (<2-log10 decline in HCV RNA), to peginterferon/ribavirin. Patients in the control arms of boceprevir Phase 2/3 studies who did not achieve SVR were re-treated with BOC/PR for up to 44 weeks. Patients enrolling >2 weeks after end-of-treatment in the prior study received PR for 4 weeks before adding boceprevir. Of 168 patients enrolled, four discontinued from the PR lead-in and 164 received BOC/PR. Baseline viral load was >800,000 IU/ml in 77% of patients; 62% had HCV genotype 1a, and 10% were cirrhotic. In the ITT analysis (all 168 patients), SVR was achieved in 20 (38%) of 52 patients with prior null response, 57 (67%) of 85 with prior partial response, and 27 (93%) of 29 with prior relapse. In the mITT analysis (164 BOC/PR-treated patients), SVR rates were 41% (20/49), 67% (57/85), and 96% (27/28), respectively. SVR was achieved by 48% of patients with <1-log10 decline in HCV-RNA after lead-in and 76% of those with ⩾1-log10 decline or undetectable HCV-RNA after lead-in. The most common adverse events were anemia (49%), fatigue (48%), and dysgeusia (35%); 8% of patients discontinued due to adverse events. Re-treatment with BOC/PR improved SVR rates in all patient subgroups, including those with prior null response." @default.
• W2169082093 created "2016-06-24" @default.
• W2169082093 creator A5000243107 @default.
• W2169082093 creator A5002042388 @default.
• W2169082093 creator A5004344876 @default.
• W2169082093 creator A5004469970 @default.
• W2169082093 creator A5013246678 @default.
• W2169082093 creator A5018022782 @default.
• W2169082093 creator A5021954687 @default.
• W2169082093 creator A5037852458 @default.
• W2169082093 creator A5038247507 @default.
• W2169082093 creator A5038426997 @default.
• W2169082093 creator A5042613443 @default.
• W2169082093 creator A5044983037 @default.
• W2169082093 creator A5046835105 @default.
• W2169082093 creator A5052196721 @default.
• W2169082093 creator A5057909457 @default.
• W2169082093 creator A5067141465 @default.
• W2169082093 creator A5068300683 @default.
• W2169082093 creator A5073144925 @default.
• W2169082093 creator A5073412832 @default.
• W2169082093 creator A5075322332 @default.
• W2169082093 creator A5086628652 @default.
• W2169082093 creator A5087810948 @default.
• W2169082093 creator A5089947807 @default.
• W2169082093 date "2014-04-01" @default.
• W2169082093 modified "2023-10-17" @default.
• W2169082093 title "Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response" @default.
• W2169082093 cites W1989022528 @default.
• W2169082093 cites W2016278419 @default.
• W2169082093 cites W2033188121 @default.
• W2169082093 cites W2044786295 @default.
• W2169082093 cites W2046658390 @default.
• W2169082093 cites W2054100924 @default.
• W2169082093 cites W2064546869 @default.
• W2169082093 cites W2075282196 @default.
• W2169082093 cites W2086667773 @default.
• W2169082093 cites W2098036743 @default.
• W2169082093 cites W2134194979 @default.
• W2169082093 cites W2141214317 @default.
• W2169082093 cites W2143559032 @default.
• W2169082093 cites W2146956830 @default.
• W2169082093 doi "https://doi.org/10.1016/j.jhep.2013.12.013" @default.
• W2169082093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24362076" @default.
• W2169082093 hasPublicationYear "2014" @default.
• W2169082093 type Work @default.
• W2169082093 sameAs 2169082093 @default.
• W2169082093 citedByCount "38" @default.
• W2169082093 countsByYear W21690820932014 @default.
• W2169082093 countsByYear W21690820932015 @default.
• W2169082093 countsByYear W21690820932016 @default.
• W2169082093 countsByYear W21690820932017 @default.
• W2169082093 countsByYear W21690820932018 @default.
• W2169082093 countsByYear W21690820932021 @default.
• W2169082093 countsByYear W21690820932022 @default.
• W2169082093 crossrefType "journal-article" @default.
• W2169082093 hasAuthorship W2169082093A5000243107 @default.
• W2169082093 hasAuthorship W2169082093A5002042388 @default.
• W2169082093 hasAuthorship W2169082093A5004344876 @default.
• W2169082093 hasAuthorship W2169082093A5004469970 @default.
• W2169082093 hasAuthorship W2169082093A5013246678 @default.
• W2169082093 hasAuthorship W2169082093A5018022782 @default.
• W2169082093 hasAuthorship W2169082093A5021954687 @default.
• W2169082093 hasAuthorship W2169082093A5037852458 @default.
• W2169082093 hasAuthorship W2169082093A5038247507 @default.
• W2169082093 hasAuthorship W2169082093A5038426997 @default.
• W2169082093 hasAuthorship W2169082093A5042613443 @default.
• W2169082093 hasAuthorship W2169082093A5044983037 @default.
• W2169082093 hasAuthorship W2169082093A5046835105 @default.
• W2169082093 hasAuthorship W2169082093A5052196721 @default.
• W2169082093 hasAuthorship W2169082093A5057909457 @default.
• W2169082093 hasAuthorship W2169082093A5067141465 @default.
• W2169082093 hasAuthorship W2169082093A5068300683 @default.
• W2169082093 hasAuthorship W2169082093A5073144925 @default.
• W2169082093 hasAuthorship W2169082093A5073412832 @default.
• W2169082093 hasAuthorship W2169082093A5075322332 @default.
• W2169082093 hasAuthorship W2169082093A5086628652 @default.
• W2169082093 hasAuthorship W2169082093A5087810948 @default.
• W2169082093 hasAuthorship W2169082093A5089947807 @default.
• W2169082093 hasConcept C126322002 @default.
• W2169082093 hasConcept C142462285 @default.
• W2169082093 hasConcept C197934379 @default.
• W2169082093 hasConcept C203014093 @default.
• W2169082093 hasConcept C2522874641 @default.
• W2169082093 hasConcept C2776235749 @default.
• W2169082093 hasConcept C2776408679 @default.
• W2169082093 hasConcept C2776455275 @default.
• W2169082093 hasConcept C2777159539 @default.
• W2169082093 hasConcept C2778159067 @default.
• W2169082093 hasConcept C2778248108 @default.
• W2169082093 hasConcept C2780040827 @default.
• W2169082093 hasConcept C71924100 @default.
• W2169082093 hasConcept C90924648 @default.
• W2169082093 hasConceptScore W2169082093C126322002 @default.
• W2169082093 hasConceptScore W2169082093C142462285 @default.
• W2169082093 hasConceptScore W2169082093C197934379 @default.
• W2169082093 hasConceptScore W2169082093C203014093 @default.
• W2169082093 hasConceptScore W2169082093C2522874641 @default.

• next